Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 16/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070359 | 0.88 | RET (0.44) | RETSSTR4BACE1BACE2 | |
| SCHEMBL20147606 | 0.87 | RET (0.48) | RET | |
| SCHEMBL20626719 | 0.87 | RET (0.48) | RETGRIN2B | |
| SCHEMBL20069614 | 0.80 | RET (0.54) | RETSSTR4 | |
| SCHEMBL20069794 | 0.78 | RET (0.51) | RET | |
| SCHEMBL20070357 | 0.76 | RET (0.47) | RETSSTR4 | |
| SCHEMBL20069734 | 0.75 | RET (0.50) | RET | |
| SCHEMBL20147635 | 0.75 | RET (0.43) | RETBACE1BACE2 | |
| SCHEMBL20069176 | 0.74 | RET (0.44) | RET | |
| SCHEMBL20068862 | 0.73 | RET (0.46) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885SSTR4 2604/4885GRIN2B 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.